Nuvilex Making Great Strides in Medical Marijuana Initiativesadmin
Baltimore, Maryland / January 13, 2014 / ACCESSWIRE / In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that driven by its steps in recent weeks, Nuvilex, Inc.’s (OTCQB – NVLX) medical marijuana initiatives may take center stage for a spell, and rightfully so, given the shift in sentiment by consumers and investors alike.
In the 21st century, certain trends and initiatives have moved so far and so fast that they have tend to take on a life of their own. This is clearly the case with marijuana early 2014, now that the nation has overwhelmingly changed its stance toward broad and widespread use cannabis.
For example, in the past week, the state of Colorado has legalized the sale of marijuana for recreational use, and others may elect to do so as well. Colorado expects to earn nearly $70M in annual tax revenue this year and now the state of Maryland has a legislator that believes he can get a similar bill passed. Plus, New York has now passed a medical marijuana law of its own, joining 20 other states.
Moreover, a recent CNN/ORC International poll found that fully 55% of all Americans believe that marijuana should be legal. These events are not unrelated and their correlation illustrates the recent rise in interest and driver of stocks with exposure to the space in the capital markets along with a major rise in the development and use of medical marijuana as well as the use of marijuana for recreational purposes.
At the end of 2013, Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., announced that it appointed Dr. Mark L. Rabe, a leading figure in the field, as Chairman of its Scientific Advisory Board. Dr. Rabe was Chief Medical Officer of California’s largest network of physician-owned medical cannabis evaluation centers. In that position, he helped provide over 100,000 medical Cannabis recommendations to patients in 20 different clinics across the state.
In addition, Nuvilex recently announced that Richard M. Hyslop, Ph.D. has agreed to join the Scientific Advisory Board of Medical Marijuana Sciences, Inc. as well. Dr. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado, has expertise in anti-cancer drug design, the metabolism of anti-cancer drugs and studies of enzymes and enzyme-catalyzed reactions in biological tissues.
Dr. Hyslop’s experience with cancer drugs and enzymology could prove to be invaluable in pursuing the goals of Medical Marijuana Sciences that include developing treatments, which employ constituents of Cannabis together with the Cell-in-a-Box™ cellulose-based live-cell encapsulation technology, whose rights were acquired by Nuvilex in 2013, for some of the deadliest forms of cancer. Dr. Hyslop’s location in the most high profile state in the country that has legalized the use of marijuana for medicinal purposes could be a further boon to the Company’s R&D efforts.
With the addition of these two figures, Nuvilex appears to be methodically building a strong foundation in the medical marijuana space with some of the leading experts in the field; this could ultimately position the Company to emerge as a leader in the multi-billion dollar marijuana industry.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A sponsored Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com/.
About Nuvilex, Inc. (OTCQB – NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: http://www.nuvilex.com/.
Goldman Small Cap Research
Rob Goldman, Analyst
Posted: January 13th, 2014 under ACCESSWIRE.